Temporomandibular Joint and COVID-19

Recep Tayyip Erdogan University Training and Research Hospital

Status: Completed

Conditions: COVID-19; ASA Triad; Temporomandibular Disorder

Treatments: Other: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale

Study type: Observational

Funder types: Other

Identifiers

NCT05077189

2020/224

Details and patient eligibility

About

There is evidence that CV-19 is associated with joint symptoms, but there are no specific data on the temporomandibular joint (TMJ). It is also known that the systemic health status can impact the immune system. Given all this, this study aimed to investigate the effect of CV-19 and systemic health status, as determined by the American Society of Anesthesiologists (ASA) Physical Status Classification System 12, on TMJ in patients with TMJ complaints using the DC/TMD scale.

Full description

This study investigates the effect of systemic status, according to American Society of Anesthesiologist (ASA), and COVID-19 on temporomandibular joint (TMJ) disorders using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale, shown to be valid for assessing TMJ disorders. The study included 76 patients who presented to our clinic with TMJ. Participants were divided into two groups: those with COVID-19 (CV-19, study group) and those without (non-CV-19, control group). These two groups were both further divided into subgroups according to ASA 1 and ASA 2 classification. Power analyses were performed using G*Power software to determine the required number of patients. Groups were compared using the Symptom Questionnaire, a demographics survey, the Graded Chronic Pain Scale (GCPS), and the Jaw Functional Limitation Scale-20 (JFLS-20) of the DC/TMD. The statistical software program version 1.6.23 was used for statistical analysis. Although joint complaints were more common in ASA 2 patients with CV-19, the groups were not significantly different. The CV-19 ASA 2 group had the highest JFLS-20 score (mean: 1.3±1.5) and the non-CV-19 ASA 1 group had the lowest JFLS-20 score (mean: 0.7±0.8), but the differences were again not significant. Joint complaints were more common and more severe in ASA 2 patients with CV-19, albeit not with statistical significance. More studies are needed to better understand our results.

Enrollment: 76 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• applied to our clinic with TMJ discomfort
• ASA 1 and ASA 2 patients

Exclusion criteria

• patients with acute CV-19
• Patients who are not in ASA 1 or ASA 2 classification
• Patients under 18 year-old
• Pregnants

Trial design

76 participants in 2 patient groups

Study Group

Description:

Patients with CV-19 and not in the acute period. This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).

Treatment:

Other: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale

Control Group

Description:

Patients without CV-19 This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).

Treatment:

Other: Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale